Preventing HPV-related cervical and anal cancers in people living with HIV across California, Mexico, and Puerto Rico
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations
This program tries new, less-invasive screening and follow-up approaches to find and treat early HPV-related precancers in people living with HIV, especially women in Mexico and Puerto Rico and men who have sex with men.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11400882 on NIH RePORTER |
What this research studies
You may be asked to give cervical or anal samples and complete a brief health history at clinics in Mexico or Puerto Rico as part of this program. One large study will invite about 4,000 HIV-positive women to try combinations of tests such as liquid-based cytology, rapid HPV genotyping, E6/E7 oncoprotein checks, and viral or host DNA methylation markers to spot high-grade cervical lesions. About 1,000 HIV-positive men who have sex with men will be screened for anal high-grade lesions to identify candidates for linked treatment studies. If abnormal results are found, participants could be referred for further follow-up or to treatment studies included in the program.
Who could benefit from this research
Good fit: Ideal candidates are adults (21+) living with HIV—particularly HIV-positive women in Mexico and Puerto Rico for cervical screening and HIV-positive men who have sex with men for anal screening.
Not a fit: People without HIV, those under study age limits, those outside the participating regions, or people already diagnosed with invasive cervical or anal cancer are unlikely to benefit directly from enrolling.
Why it matters
Potential benefit: If successful, the program could help catch cervical and anal precancers earlier and reduce progression to cancer in people living with HIV.
How similar studies have performed: HPV DNA testing and cytology have helped detect precancers in general populations, but applying newer oncoprotein and methylation tests specifically in HIV-positive people in Latin America is relatively new and less proven.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Palefsky, Joel Michael — University of California, San Francisco
- Study coordinator: Palefsky, Joel Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.